Nkarta, Inc. · NASDAQ:NKTX
Nkarta — EHA 2023
15 slides from Nkarta's conference presentation, Jun 10, 2023
Slide 1: First in Human Data of NKX019, an Allogeneic CAR NK for r/r B-cell Malignancies
| FIRST IN HUMAN DATA OF NKX019, AN ALLOGENEIC CAR NK FOR THE TREATMENT OF RELAPSED/REFRACTORY (R/R) B-CELL MALIGNANCIES 10-06-23
Slide 2: First in Human Data of NKX019, an Allogeneic CAR NK for the Treatment of r/r B-cell Malignancies
First in Human Data of NKX019, an Allogeneic CAR NK for the Treatment of Relapsed/refractory (r/r) B-cell Malignancies Michael Dickinson1, Nada Hamad2, Christian Bryant3, Nishi Kothari4, Paulius Ojeras4, Anmol Vohra4, Ming Lin4, Mira Tohme4, James Trager4, David Shook4, Glen Kennedy5, Michael Tees6,
Slide 3: Disclosures: A/Prof Michael Dickinson
Disclosures: A/Prof Michael Dickinson Consultant or advisory role: AbbVie, BMS, Gilead, Novartis, Roche; Janssen; Genmab Honoraria: Roche; Amgen; Janssen; BMS; Novartis; Gilead; AbbVie Research funding: Celgene; Gilead, Novartis, Roche; Takeda; Lilly; MSD Travel grants: Roche
Slide 4: Autologous CAR T-cell Therapy Transformative but with Limitations
Autologous CAR T-cell Therapy Transformative but with Limitations ▪ Custom manufacturing of auto CAR T-cell therapy precludes precludes prompt treatment and can result in manufacturing failure ▪ T-cell mediated toxicities are common and can be severe, thereby limiting the population of eligible pati
Slide 5: NKX019: On Demand Allogeneic NK Based Cellular Therapy
NKX019: On Demand Allogeneic NK Based Cellular Therapy ▪ NK cells provide important antigen independent tumor surveillance and kill tumor cells via a balance of activating and inhibitory signals ▪ NKX019 is a cryopreserved, allogeneic CD19- targeting CAR NK-cell therapy, derived from healthy donors
Slide 6: A Multicenter, Open-Label, Phase 1 Study of NKX019
A Multicenter, Open-Label, Phase 1 Study of NKX019 Key Inclusion Criteria Lymphodepletion NKX019 Efficacy Post-treatment • r/r CD19+ B-cell • Cyclophosphamide 3 doses per 28-day cycle assessment* follow-up 300 mg/m2/day IV (dose- malignancies finding phase) • Received >2 prior • Fludarabine lines of
Slide 7: Baseline Characteristics
NKX019 Baseline Characteristics Total (N=19) Age, median (range) 59 (21-82) Baseline ECOG PS 1 13 Australia/US 13/6 Diagnosis Large B cell lymphoma (LBCL)# 7 IPI 3+ 3 (43%) Follicular lymphoma (FL) 5 FLIPI high risk 3 (60%) Marginal zone lymphoma (MZL) 1 Mantle cell lymphoma (MCL) 1 Chronic lymphocy
Slide 8: NKX019 Toxicity Profile
NKX019 Toxicity Profile Grade 3/4 AEs in >1 subject Total N=19 ▪ No ICANS / neurotoxicity, GVHD, Grade 5 Subjects with any ≥ Grade 3 AEs 16 (84%) Neutrophil count decreased 12 (63%) ▪ No dose-limiting toxicities Platelet count decreased 8 (42%) ▪ One (5%) Grade ≥ 3 infection Febrile neutropenia 5 (2
Slide 9: Transient and Manageable Infusion-Related Effects
Transient and Manageable Infusion-Related Effects 5/19 patients (26%) developed fever within 8 hours that resolved within 24 hours Investigator Anti-IL-6 Patient Grade Steroids Description of event assessment therapy #1 G1 IRR N N Fever within 8 hours; resolved with antipyretics and did not recur #2
Slide 10: Modest Cytokine Change from Baseline
Modest Cytokine Change from Baseline Cytokine Fold-Change per Cycle ▪ IL-6, IFNγ, IL-10, and IL-8 levels 100 CR were measured at baseline and Maximum Fold-Change Non-CR several timepoints during the 28 10 day treatment cycle ▪ Minimal elevations above baseline 1 ▪ No association between elevated ser
Slide 11: Efficacy Across Histologies
Efficacy Across Histologies NHL Best Patient Cells Subtype Response 14 1.5 B FL CR 13 1.5 B LBCL CR 12 1.5 B FL CR 11 1.5 B LBCL SD 10 1.0 B LBCL CR 9 1.0 B MZL CR 8 1.0 B FL CR 7 1.0 B MCL CR 6 1.0 B FL PR 5 1.0 B LBCL SD 4 300 M FL CR 3 300 M FL3b PR 2 300 M LBCL PD 1 300 M LBCL PD As of Nov 22 da
Slide 12: Tumor Reduction with NKX019
Tumor Reduction with NKX019 0 Maximum Change From Baseline -20 Tumor Size (%) -40 -60 Best Response CR -80 PR SD PD -100 One patient discontinued therapy after a single dose and did not have follow up evaluation As of Nov 22 data cut CR: complete response; NHL: non-Hodgkin lymphoma; PD: progressive
Slide 13: NKX019 at Higher Doses Correlated with Higher Cmax
NKX019 at Higher Doses Correlated with Higher Cmax Dose Level Cmax All subjects CR Non-CR n 5 1 4 300 M cells Median < 6.7 393 < 6.7 (range) (< 6.7-393) (393) (< 6.7-234) n 14 7 7 1 B/1.5 B cells Median 156.9 298 < 6.7 (range) (< 6.7-567.0) (< 6.7-567.0) (< 6.7-481) 6.7 = Lower limit of quantificati
Slide 14: Conclusions
Conclusions ▪ NKX019 had no DLTs, ICANS, GVHD, or Grade > 3 CRS ▪ At highest dose levels, 8 of 10 patients with NHL responded (80% ORR), and 7 of 10 patients achieved complete responses (70% CR), including 50% CR in LBCL ▪ Deep responses with durability > 6 months in multiple patients with potential
Slide 15: Acknowledgements
Acknowledgements ▪ We thank the individuals who participated in the study, their families, and study personnel ▪ Funding source: Nkarta Therapeutics